iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Update

iBio, Inc. (NYSEAMERICAN:IBIO) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 184,500 shares, a growth of 14.1% from the March 31st total of 161,700 shares. Approximately 2.2% of the shares of the stock are short sold. Based on an average daily volume of 3,720,000 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on iBio in a report on Wednesday, March 27th. They set a “sell” rating on the stock.

iBio Stock Performance

iBio stock traded down $0.10 during mid-day trading on Monday, hitting $1.66. The stock had a trading volume of 292,887 shares, compared to its average volume of 2,971,024. iBio has a 12 month low of $1.02 and a 12 month high of $22.80. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04.

iBio (NYSEAMERICAN:IBIO) last issued its earnings results on Friday, February 9th. The company reported ($2.42) earnings per share (EPS) for the quarter.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.